JP2018528199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528199A5 JP2018528199A5 JP2018510352A JP2018510352A JP2018528199A5 JP 2018528199 A5 JP2018528199 A5 JP 2018528199A5 JP 2018510352 A JP2018510352 A JP 2018510352A JP 2018510352 A JP2018510352 A JP 2018510352A JP 2018528199 A5 JP2018528199 A5 JP 2018528199A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal form
- group
- powder
- independently selected
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015088003 | 2015-08-25 | ||
| CNPCT/CN2015/088003 | 2015-08-25 | ||
| PCT/CN2016/096200 WO2017032289A1 (en) | 2015-08-25 | 2016-08-22 | Process for preparing parp inhibitor, crystalline forms, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528199A JP2018528199A (ja) | 2018-09-27 |
| JP2018528199A5 true JP2018528199A5 (https=) | 2019-09-26 |
| JP6940039B2 JP6940039B2 (ja) | 2021-09-22 |
Family
ID=58099633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510352A Expired - Fee Related JP6940039B2 (ja) | 2015-08-25 | 2016-08-22 | Ｐａｒｐ阻害剤の製造方法、結晶型、及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10457680B2 (https=) |
| EP (1) | EP3341375B1 (https=) |
| JP (1) | JP6940039B2 (https=) |
| KR (1) | KR20180041748A (https=) |
| CN (2) | CN107922425B (https=) |
| AU (1) | AU2016312011B2 (https=) |
| BR (1) | BR112018003634B1 (https=) |
| CA (1) | CA2994895A1 (https=) |
| EA (1) | EA037366B1 (https=) |
| IL (2) | IL296835A (https=) |
| MX (1) | MX385450B (https=) |
| NZ (1) | NZ739876A (https=) |
| TW (1) | TWI736550B (https=) |
| WO (1) | WO2017032289A1 (https=) |
| ZA (1) | ZA201800765B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN06169A (https=) | 2011-12-31 | 2015-08-21 | Beigene Ltd | |
| EP3341375B1 (en) | 2015-08-25 | 2022-04-13 | BeiGene, Ltd. | Process for preparing parp inhibitor, crystalline forms, and uses thereof |
| CN110087730B (zh) * | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
| TW201840564A (zh) | 2017-02-28 | 2018-11-16 | 英屬開曼群島商百濟神州有限公司 | 稠合的四環或五環二氫二氮呯幷哢唑酮的鹽的結晶形式及其用途 |
| US12121518B2 (en) | 2017-03-09 | 2024-10-22 | The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College | PARP-1 and methods of use thereof |
| WO2018165615A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
| US20200155567A1 (en) * | 2017-07-17 | 2020-05-21 | Beigene, Ltd. | Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy |
| JP7407740B2 (ja) | 2018-05-18 | 2024-01-04 | ノバルティス アーゲー | Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態 |
| WO2019228499A1 (en) * | 2018-06-01 | 2019-12-05 | Beigene, Ltd. | Maintenance therapy of a parp inhibitor in treating gastric cancer |
| USD926356S1 (en) * | 2019-03-14 | 2021-07-27 | Tuanfang Liu | Battery for electronic cigarette |
| CN111171031B (zh) * | 2019-05-10 | 2021-04-09 | 百济神州(苏州)生物科技有限公司 | 一种含parp抑制剂倍半水合物产物的制备方法 |
| CN111171002B (zh) * | 2019-05-16 | 2021-04-06 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体的制备方法 |
| CN111171001B (zh) * | 2019-05-16 | 2022-04-29 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体的结晶方法 |
| CN112007011B (zh) * | 2019-05-31 | 2024-07-23 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂微丸胶囊及其制备工艺 |
| KR20220016028A (ko) * | 2019-05-31 | 2022-02-08 | 베이진 엘티디 | Parp 억제제 펠릿 제조 및 이의 제조방법 |
| WO2021046014A1 (en) | 2019-09-03 | 2021-03-11 | Teva Czech Industries S.R.O | Solid state forms of pamiparib and process for preparation thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA11749A (en) | 1999-01-11 | 2005-07-19 | Agouron Pharma | Tricyclic inhibitors of poly(adp-ribose)polymerases. |
| MXPA03004832A (es) | 2000-12-01 | 2004-05-04 | Guilford Pharm Inc | Compuestos y sus usos. |
| CA2512683C (en) * | 2003-01-09 | 2010-03-16 | Pfizer Inc. | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy |
| ES2625817T3 (es) | 2008-08-06 | 2017-07-20 | Medivation Technologies, Inc. | Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
| IN2014DN06169A (https=) * | 2011-12-31 | 2015-08-21 | Beigene Ltd | |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| EP3341375B1 (en) | 2015-08-25 | 2022-04-13 | BeiGene, Ltd. | Process for preparing parp inhibitor, crystalline forms, and uses thereof |
| CN110087730B (zh) * | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
| TW201840564A (zh) | 2017-02-28 | 2018-11-16 | 英屬開曼群島商百濟神州有限公司 | 稠合的四環或五環二氫二氮呯幷哢唑酮的鹽的結晶形式及其用途 |
| US20200155567A1 (en) | 2017-07-17 | 2020-05-21 | Beigene, Ltd. | Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy |
| CN111171031B (zh) * | 2019-05-10 | 2021-04-09 | 百济神州(苏州)生物科技有限公司 | 一种含parp抑制剂倍半水合物产物的制备方法 |
-
2016
- 2016-08-22 EP EP16838548.2A patent/EP3341375B1/en not_active Not-in-force
- 2016-08-22 EA EA201890547A patent/EA037366B1/ru not_active IP Right Cessation
- 2016-08-22 CA CA2994895A patent/CA2994895A1/en active Pending
- 2016-08-22 BR BR112018003634-0A patent/BR112018003634B1/pt not_active IP Right Cessation
- 2016-08-22 IL IL296835A patent/IL296835A/en unknown
- 2016-08-22 JP JP2018510352A patent/JP6940039B2/ja not_active Expired - Fee Related
- 2016-08-22 US US15/753,993 patent/US10457680B2/en active Active
- 2016-08-22 MX MX2018002322A patent/MX385450B/es unknown
- 2016-08-22 IL IL257442A patent/IL257442B2/en unknown
- 2016-08-22 WO PCT/CN2016/096200 patent/WO2017032289A1/en not_active Ceased
- 2016-08-22 NZ NZ739876A patent/NZ739876A/en not_active IP Right Cessation
- 2016-08-22 KR KR1020187008548A patent/KR20180041748A/ko not_active Ceased
- 2016-08-22 CN CN201680048637.5A patent/CN107922425B/zh active Active
- 2016-08-22 AU AU2016312011A patent/AU2016312011B2/en not_active Ceased
- 2016-08-22 CN CN202011223061.6A patent/CN112521390A/zh active Pending
- 2016-08-24 TW TW105127160A patent/TWI736550B/zh not_active IP Right Cessation
-
2018
- 2018-02-06 ZA ZA201800765A patent/ZA201800765B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528199A5 (https=) | ||
| JP2018511634A5 (https=) | ||
| EP3248983B1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
| JP2005503386A5 (https=) | ||
| JPWO2003008421A1 (ja) | アミジン誘導体の製造方法 | |
| JP2002519422A (ja) | パロキセチンメタンスルホネート | |
| ES2575000T3 (es) | Proceso mejorado para la preparación de ambrisentano | |
| JP2020033359A5 (https=) | ||
| JP6779972B2 (ja) | 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形 | |
| JP2003286287A (ja) | 塩酸エピナスチン高融点型結晶の製造法 | |
| WO2018117267A1 (ja) | 置換ピペリジン化合物の塩 | |
| JP6225998B2 (ja) | インドリン化合物の製造方法 | |
| CN102675395B (zh) | 醋酸乌利司他的多晶型及其制备方法 | |
| AU2011284341A1 (en) | N-Methylformamide solvate of dasatinib | |
| EP3565819A2 (en) | Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate | |
| JPWO2016175305A1 (ja) | アシルチオウレア化合物のメシル酸塩及びその結晶並びにそれらの製造方法 | |
| JP2007524569A (ja) | ナテグリニドの結晶形 | |
| CN110372635B (zh) | 氢溴酸沃替西汀α晶型的制备方法 | |
| JP2006511614A (ja) | ナテグリニドの多形性形状 | |
| JP6913692B2 (ja) | オキサチアジン様化合物を作製する方法 | |
| JP7340534B2 (ja) | トレプロスチニルジエタノールアミン塩の多形形態ｂを製造するための方法 | |
| CN109535060B (zh) | 一种刺猬通路抑制剂及其制备方法和应用 | |
| CA3048771C (en) | Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate | |
| WO2013013594A1 (zh) | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的无定形物及其制备方法 | |
| CN119431359A (zh) | 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途 |